'Atazanavir' presentation slideshows

Post-Exposure Prophylaxis an evidence-based review

Post-Exposure Prophylaxis an evidence-based review. Christopher Behrens, MD Hillary Liss, MD Northwest AIDS Education & Training Center University of Washington. Post-Exposure Prophylaxis (PEP). The use of therapeutic agents to prevent infection following exposure to a pathogen

1.13k views • 71 slides

Antiretroviral Combinations

Antiretroviral Combinations. James A Zachary MD LSU Health Sciences Center HIV Outpatient Clinic December 13, 2004 http://HIVManagement.org. Objectives. Review rationale for combinations Review basis of protease inhibitor interactions Review specific combinations (mainly PI)

579 views • 42 slides

Update on Atazanavir and the Early Access Program

Update on Atazanavir and the Early Access Program. AIDS Treatment Activists Coalition Seattle, Washington February 24 2001. Atazanavir Profile. Azapeptide inhibitor of HIV protease Dosed 400 mg QD with food (2 capsules) Favorable potency and resistance profile

526 views • 41 slides

588 views • 33 slides

ANTIRETROVIRAL DRUGS IN THE PERINATAL PERIOD

ANTIRETROVIRAL DRUGS IN THE PERINATAL PERIOD. Use of ARV Drugs by HIV-Infected Pregnant Women and Their Infants. Considerations for choice of ARV drugs for pregnant women include: Possible changes in dosing requirements resulting from physiologic changes associated with pregnancy

339 views • 20 slides

Atazanavir Impurities Manufacturer | Suppliers | Hemarsh Technologies

Atazanavir Impurities Manufacturer and suppliers in India - Hemarsh Technologies was established in 2008 and since then our company has enjoyed a rapid growth. Our prime focus is on contract research and impurities synthesis for pharmaceutical industries.

155 views • 15 slides